Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Receivables - Other: 2023-2024

Historic Receivables - Other for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $1.5 million.

  • BioLineRx's Receivables - Other fell 69.05% to $203,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $203,000, marking a year-over-year decrease of 69.05%. This contributed to the annual value of $1.5 million for FY2024, which is 78.07% up from last year.
  • Latest data reveals that BioLineRx reported Receivables - Other of $1.5 million as of FY2024, which was up 78.07% from $830,000 recorded in FY2023.
  • Over the past 5 years, BioLineRx's Receivables - Other peaked at $1.5 million during FY2024, and registered a low of $830,000 during FY2023.
  • Its 2-year average for Receivables - Other is $1.2 million, with a median of $1.2 million in 2023.
  • As far as peak fluctuations go, BioLineRx's Expense - Property Taxes and Insurance increased by 6.16% in 2015, and later declined by 0.65% in 2016.
  • BioLineRx's Expense - Property Taxes and Insurance (Yearly) stood at $142,000 in 2013, then increased by 2.82% to $146,000 in 2014, then increased by 6.16% to $155,000 in 2015, then decreased by 0.65% to $154,000 in 2016.